Integrated whole genome microarray analysis and immunohistochemical assay identifies COL11A1, GJB2 and CTRL as predictive biomarkers for pancreatic cancer

BackgroundPancreatic cancer is characterized by its unsatisfying early detection rate, rapid disease progression and poor prognosis. Further studies on molecular mechanism and novel predictive biomarkers for pancreatic cancer based on a large sample volume are required.MethodsMultiple bioinformatic analysis tools were utilized for identification and characterization of differentially expressed genes (DEGs) from a merged microarray data (100 pancreatic cancer samples and 62 normal samples). Data from the GEO and TCGA database was utilized to validate the diagnostic and prognostic value of the top 5 upregulated/downregulated DEGs. Immunohistochemical assay (46 paired pancreatic and para- cancerous samples) was utilized to validate the expression and prognostic value of COL11A1, GJB2 and CTRL from the identified DEGs.ResultsA total number of 300 DEGs were identified from the merged microarray data of 100 pancreatic cancer samples and 62 normal samples. These DEGs were closely correlated with the biological characteristics of pancreatic cancer. The top 5 upregulated/downregulated DEGs showed good individual diagnostic/prognostic value and better combined diagnostic/prognostic value. Validation of COL11A1, GJB2 and CTRL with immunohistochemical assay showed consistent expression level with bioinformatics analysis and promising prognostic value.ConclusionsMerged microarray data with bigger sample volume could reflect the biological characteristics of pancreatic cancer more effectively and accurately. COL11A1, GJB2 and CTRL are novel predictive biomarkers for pancreatic cancer.

[1]  The Gene Ontology Consortium.  Expansion of the Gene Ontology knowledgebase and resources , 2016, Nucleic Acids Res..

[2]  X. Tan,et al.  Quantitative secretomic analysis of pancreatic cancer cells in serum-containing conditioned medium , 2016, Scientific Reports.

[3]  Yang Jiang,et al.  Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. , 2017, Journal of neurosurgery.

[4]  Y. Yoshida,et al.  Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma , 2018, Cancer science.

[5]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[6]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[7]  The Gene Ontology Consortium,et al.  Expansion of the Gene Ontology knowledgebase and resources , 2016, Nucleic Acids Res..

[8]  M. Falasca,et al.  Emerging role of the KRAS-PDK1 axis in pancreatic cancer. , 2014, World journal of gastroenterology.

[9]  Xuexiang Han,et al.  A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. , 2017, Cancer letters.

[10]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[11]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[12]  M. Ebert,et al.  Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  K. Guan,et al.  eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth. , 2017, Cancer research.

[14]  S. Choi,et al.  Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients , 2013, Cancer Chemotherapy and Pharmacology.

[15]  Hong Wu,et al.  Integrative Survival-Based Molecular Profiling of Human Pancreatic Cancer , 2012, Clinical Cancer Research.

[16]  Clement Adebamowo,et al.  A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. , 2018, Cancer cell.

[17]  Min Zhang,et al.  lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. , 2018, Cancer cell.

[18]  M. Hidalgo.  Pancreatic cancer. , 2010, The New England journal of medicine.

[19]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[20]  Brad T. Sherman,et al.  DAVID-WS: a stateful web service to facilitate gene/protein list analysis , 2012, Bioinform..

[21]  Yang Liu,et al.  Bioinformatic profiling identifies an immune-related risk signature for glioblastoma , 2016, Neurology.

[22]  S. Kizaka-Kondoh,et al.  Novel lymphoid enhancer‐binding factor 1‐cytoglobin axis promotes extravasation of osteosarcoma cells into the lungs , 2018, Cancer science.

[23]  X. Tan,et al.  Exosomal zinc transporter ZIP4 promotes cancer growth and is a novel diagnostic biomarker for pancreatic cancer , 2018, Cancer science.

[24]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  B. Hoffman,et al.  Clinical Investigation : Gastrointestinal Cancer Phase 2 Trial of Induction Gemcitabine , Oxaliplatin , and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer , 2022 .

[26]  Krishna R. Kalari,et al.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. , 2009, Cancer cell.

[27]  L. Wood,et al.  A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. , 2017, Cancer cell.

[28]  X. Tan,et al.  The role of pancreatic cancer-derived exosomes in cancer progress and their potential application as biomarkers , 2017, Clinical and Translational Oncology.

[29]  Yang Jiang,et al.  Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma. , 2016, Journal of neurosurgery.

[30]  David Westhead,et al.  Prediction of clinical outcome in glioblastoma using a biologically relevant nine‐microRNA signature , 2015, Molecular oncology.